↓ Read PDF
01 · ABSTRACT

Abstract

Background: Hypoxic-ischemic encephalopathy (HIE) is a neurological condition that leads to motor disabilities and even death in neonates. Unfortunately, few therapeutic alternatives can contribute to brain recovery after HIE damage. Cerebrolysin is a neuropeptide mixture that exerts neuroprotective and neurotrophic effects on injured brain tissue after systemic administration.

Aims: This study evaluated the short- and long-term beneficial effects of Cerebrolysin administration in a rat model of HIE.

Methods: Neonatal 7-day-old rats were subjected to hypoxia-ischemia injury and then intraperitoneally administered Cerebrolysin (10 mL/kg of body weight) once a day for 7 days, from postnatal days 8 to 14. Growth development, blood-brain barrier permeability, and neurobehavioral tests were performed.

Results: Cerebrolysin administration after hypoxic-ischemic insult minimized brain damage, edema and increased cellular viability. Furthermore, this neuroprotective effect improves some motor abnormalities and, during adulthood, reverses the long-term memory acquisition deficit caused by HIE.

Conclusion: Repeated Cerebrolysin administration can safely and effectively reduce HIE motor disabilities and reverse long-term memory acquisition deficits in neonatal rats.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 11 No 8 (2023): August Issue, Vol.11, Issue 8
SectionResearch Articles
Published31 August 2023
DOI10.18103/mra.v11i8.4345
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

EB

Ericka Barrientos-Zavalza, MSc

Doctorado en Ciencias Biológicas y de la Salud. Universidad Autónoma Metropolitana. CDMX, México; Área de Neurociencias. Departamento de Biología de la Reproducción, Universidad Autónoma Metropolitana-Iztapalapa. CDMX; Laboratorio de Medicina Genómica. Hospital Regional " Primero de Octubre", ISSSTE. CDMX, México; Departamento de Fisiología, Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, CDMX, México

CP

Celia Piña-Leyva, Dr

Departamento de Fisiología, Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, CDMX, México

ML

Manuel Lara-Lozano, Dr

Departamento de Fisiología, Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, CDMX, México

GF

Gonzalo Flores, Dr

Instituto de Fisiología, Benemérita Universidad Autónoma de Puebla. Puebla, México

DM

Daniel Martínez-Fong, Dr

Departamento de Fisiología, Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, CDMX, México; Programa de doctorado en Nanomedicina y Nanotecnología. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional. CDMX; Nanoparticle Therapy Institute, Aguascalientes, Aguascalientes, México

BL

Bertha Alicia León-Chávez, Dr

Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla. Puebla, México

AJ

Anabel Jiménez-Anguiano, Dr

Área de Neurociencias. Departamento de Biología de la Reproducción, Universidad Autónoma Metropolitana-Iztapalapa. CDMX

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗